588 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
MS Morgan Stanley $47.68 $83.19B N/A
Article Searches
Analysts Estimate Morgan Stanley (MS) to Report a Decline in Earnings: What to Look Out for http://www.zacks.com/stock/news/377580/analysts-estimate-morgan-stanley-ms-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-377580 Apr 10, 2019 - Morgan Stanley (MS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA OKs Merck KGaA's MS med Mavenclad https://seekingalpha.com/news/3447073-fda-oks-merck-kgaas-ms-med-mavenclad?source=feed_news_all Mar 30, 2019 - The FDA approves Merck KGaA (OTCPK:MKGAY) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS).Because of its safety profile, the dr
Novartis (NVS) Receives FDA Approval for MS Drug Mayzent http://www.zacks.com/stock/news/365815/novartis-nvs-receives-fda-approval-for-ms-drug-mayzent?cid=CS-ZC-FT-365815 Mar 27, 2019 - Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.
Celgene (CELG) Submits NDA for MS Drug to FDA for Review http://www.zacks.com/stock/news/365034/celgene-celg-submits-nda-for-ms-drug-to-fda-for-review?cid=CS-ZC-FT-365034 Mar 26, 2019 - Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.
Celgene files U.S. application for MS med ozanimod https://seekingalpha.com/news/3445524-celgene-files-u-s-application-ms-med-ozanimod?source=feed_news_all Mar 25, 2019 - Celgene (NASDAQ:CELG) has filed a marketing application with the FDA seeking approval for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (MS).It filed an appli
Williams (WMB) Forms Marcellus, Utica JV With Canadian Fund http://www.zacks.com/stock/news/362828/williams-wmb-forms-marcellus-utica-jv-with-canadian-fund?cid=CS-ZC-FT-362828 Mar 21, 2019 - Williams (WMB) creates a $3.8-billion partnership with Canada Pension Plan Investment Board in the western Marcellus and Utica basins.
Stock Market News For Mar 21, 2019 http://www.zacks.com/stock/news/362608/stock-market-news-for-mar-21-2019?cid=CS-ZC--362608 Mar 21, 2019 - Wall Street was mostly lower on Wednesday following decline in bank stocks after the Fed decided not to hike rate in 2019.
FANG Stocks: What to Expect in 2019 https://www.fool.com/investing/2019/03/20/fang-stocks-what-to-expect-in-2019.aspx?source=iedfolrf0000001 Mar 20, 2019 - This group of high-flying tech stocks has crushed the market in recent years. Will the good times continue?
MS drug ozanimod, from Scripps Research, submitted for European approval http://www.sandiegouniontribune.com/business/sd-me-ozanimod-celgene-receptos-scripps-20190313-story.html Mar 13, 2019 -

Ozanimod, a drug for multiple sclerosis originating at Scripps Research, has been submitted for European approval by Celgene.

A U.S. Food and Drug Administration marketing application is also on track for filing by the end of March, the New Jersey-based drug company said Monday. The FDA rejected...

Top Analyst Reports for Procter & Gamble, Netflix & Costco http://www.zacks.com/research-daily/359113/top-analyst-reports-for-procter-gamble-netflix-costco?cid=CS-ZC-FT-359113 Mar 13, 2019 - Top Analyst Reports for Procter & Gamble, Netflix & Costco

Pages: 123456789...59

<<<Page 4>